Early-Onset Gastric Cancer Suggested to be Genetically and Clinically Distinct


Incidence of early-onset gastric cancer has steadily increased in the US, now comprising >30% of new gastric cancer cases today, causing researchers to try and discover what makes this disease type unique.

Early-onset gastric cancer is genetically and clinically distinct from traditional gastric cancer, according to a study published in the journal Surgery.1

With the incidence of early-onset gastric cancer steadily increasing in the US since 1995, comprising >30% of new gastric cancer cases today, researchers indicated that additional investigations are crucial to better understand this startling finding and to facilitate optimal treatment and surveillance strategies.

“I think this is an alarming trend, as stomach cancer is a devastating disease,” senior author Travis Grotz, MD, surgical oncologist at the Mayo Clinic, said in a press release.2 “There is little awareness in the US of the signs and symptoms of stomach cancer, and many younger patients may be diagnosed late – when treatment is less effective.” 

In this cohort of 75,225 cases studied from 1972 to 2015 using several cancer databases, researchers found that the incidence of late-onset stomach cancer decreased by 1.8% annually over the course of the study period, while early-onset gastric cancer decreased annually by 1.9% from 1973 to 1995 and then increased by 1.5% through 2013.

Early-onset gastric cancer was correlated with higher grade (55.2% vs 46.9%), signet-ring cells (19.0% vs 10.4%), diffuse histology (25.7% vs 15.0%), and metastatic disease (49.5% vs 40.9%, all < 0.01). Additionally, early-onset gastric cancer was more likely to be Epstein-Barr virus (7.7% vs 5.1%) or genomically stable (22.5% vs 8.1%) subtype, whereas late-onset gastric cancer was more likely to be microsatellite instability subtype (18.6% vs 5.6%; all < 0.01). Risk factors for gastric cancer were associated less with early-onset gastric cancer compared with late-onset gastric cancer. 

The average age of someone diagnosed with stomach cancer today is 68, according to the American Cancer Society, however individuals in their 30s, 40s, and 50s are more at risk now than they used to be.3“Typically, we see stomach cancer being diagnosed in patients in their 70s, but increasingly we are seeing 30- to 50-year-old patients being diagnosed,” Grotz said. 

The increased rate of the early-onset disease is not due to earlier detection or screening, according to the researchers. Moreover, traditionally associated risk factors for developing gastric cancer among older adults, such as smoking and binge drinking, were not correlated with early-onset patients.

“Hopefully studies like this will raise awareness and increase physician suspicion of stomach cancer, particularly in younger patients,” Grotz said. Younger patients who feel full before finishing a meal, or have reflux, abdominal pain, unintentional weight loss, and difficulty eating should see their healthcare provider, he added. 

The American Cancer Society estimates that in the US, 27,600 new cases of stomach cancer (16,980 in men and 10,620 in women) will diagnosed in 2020. 

The research team next hopes to better identify risk factors for early-onset gastric cancer.


1. Bergquist JR, Leiting JL, Habermann EB, et al. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery. doi:10.1016/j.surg.2019.04.036.

2. Many younger patients with stomach cancer have a distinct disease, Mayo research discovers [news release]. Rochester, Minnesota. Published December 24, 2019. newswise.com/articles/many-younger-patients-with-stomach-cancer-have-a-distinct-disease-mayo-research-discovers?sc=mwhr&xy=10024642. Accessed January 17, 2020.

3. American Cancer Society. Key Statistics About Stomach Cancer. American Cancer Society website. Published January 8, 2020. cancer.org/cancer/stomach-cancer/about/key-statistics.html. Accessed January 17, 2020. 

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content